Organic growth would be better. This transaction heavily dilutes existing shareholders. I suppose it might be that tacking the pommy business on may give Microba's servicing business critical mass but growth by dilution is a risk in my view.
Ann: Microba to acquire UK microbiome leader Invivo Clinical, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.37M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 16.8¢ | $31.35K | 184.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69019 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 74788 | 2 |
View Market Depth
| Last trade - 13.07pm 11/10/2024 (20 minute delay) ? |
| MAP (ASX) Chart |